TCIM
UBX

TIAA CREF Investment Management’s Unity Biotechnology UBX Stock Holding History

TIAA CREF Investment Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$395K Buy
4,869
+94
+2% +$10.7K ﹤0.01% 2681
2018
Q4 		$776K Buy
+4,775
New +$634K ﹤0.01% 2381

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TIAA CREF Investment Management's UBX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Unity Biotechnology (UBX) stake by 2% in Q1 2019, buying an estimated $10.7K and bringing the position to 4,869 shares worth $395K. The position accounts for ﹤0.01% of the portfolio, ranked #2681.

TIAA CREF Investment Management first reported a position in UBX in Q4 2018 and has held it in 2 quarters since. The position peaked at $776K in Q4 2018. 57 funds tracked by Wall St. Rank hold UBX as of Q1 2019.

  • TIAA CREF Investment Management held 4,869 shares of Unity Biotechnology worth $395K as of Q1 2019.
  • TIAA CREF Investment Management bought 94 Unity Biotechnology shares in Q1 2019, an estimated $10.7K.
  • Unity Biotechnology made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2681 holding.
  • TIAA CREF Investment Management first reported a position in Unity Biotechnology in Q4 2018 and has held it in 2 quarters since.
  • TIAA CREF Investment Management's Unity Biotechnology position peaked at $776K in Q4 2018.
  • 57 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.